Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RSBNAT: Recurrence Score-guided Capecitabine in Non-pCR HR+/HER2- Breast Cancer
NCT03638648Phase 2Unknown
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Nov 2019
- Primary completion
- Dec 2020
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
01
Overview
Phase 2, randomised, open-label trial of capecitabine in breast cancer (4 arms), sponsored by Zhejiang Cancer Hospital. Primary endpoint: 2-year Disease Free Survival. Status: unknown.
02
Drugs
capecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03638648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03638648.